[{"id":"111dadaf-4e0e-41c4-96f3-ff25aabf637a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03047213","created_at":"2021-01-18T15:00:26.479Z","updated_at":"2025-02-25T15:17:24.811Z","phase":"Phase 2","brief_title":"Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations","source_id_and_acronym":"NCT03047213","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TSC2 • TSC1","pipe":" | ","alterations":" TSC1 mutation • TSC2 mutation","tags":["TSC2 • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TSC1 mutation • TSC2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 08/24/2017","start_date":" 08/24/2017","primary_txt":" Primary completion: 10/06/2020","primary_completion_date":" 10/06/2020","study_txt":" Completion: 11/11/2025","study_completion_date":" 11/11/2025","last_update_posted":"2025-02-12"},{"id":"fe616f09-6291-4f55-8056-8b008452edb9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06757634","created_at":"2025-02-25T20:04:40.854Z","updated_at":"2025-02-25T20:04:40.854Z","phase":"Phase 3","brief_title":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)","source_id_and_acronym":"NCT06757634","lead_sponsor":"Celcuity Inc","biomarkers":" PIK3CA","pipe":"","alterations":" ","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Kisqali (ribociclib) • fulvestrant • gedatolisib (PF-05212384)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 674","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-01-07"},{"id":"1fa5498c-1aea-4d87-9474-f28a1ded3063","acronym":"MANTA","url":"https://clinicaltrials.gov/study/NCT02216786","created_at":"2021-01-18T10:23:25.940Z","updated_at":"2025-02-25T15:06:06.929Z","phase":"Phase 2","brief_title":"A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer","source_id_and_acronym":"NCT02216786 - MANTA","lead_sponsor":"Queen Mary University of London","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • fulvestrant • vistusertib (AZD2014)"],"overall_status":"Completed","enrollment":" Enrollment 333","initiation":"Initiation: 01/16/2014","start_date":" 01/16/2014","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2024-12-02"},{"id":"08e8d834-7d1c-43f8-b2b4-1023ee00f03e","acronym":"X31025","url":"https://clinicaltrials.gov/study/NCT03154294","created_at":"2025-09-13T10:56:31.458Z","updated_at":"2025-09-13T10:56:31.458Z","phase":"Phase 1","brief_title":"Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors","source_id_and_acronym":"NCT03154294 - X31025","lead_sponsor":"Avera McKennan Hospital \u0026 University Health Center","biomarkers":" PI3K","pipe":"","alterations":" ","tags":["PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • sapanisertib (CB-228) • serabelisib (MLN1117)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 07/06/2017","start_date":" 07/06/2017","primary_txt":" Primary completion: 11/20/2020","primary_completion_date":" 11/20/2020","study_txt":" Completion: 11/20/2022","study_completion_date":" 11/20/2022","last_update_posted":"2024-07-26"},{"id":"6c1bf2f9-a643-4b80-84fa-1e32b26a8869","acronym":"BTCRC-BRE18-337","url":"https://clinicaltrials.gov/study/NCT03911973","created_at":"2021-01-18T19:15:11.647Z","updated_at":"2024-07-02T16:34:37.336Z","phase":"Phase 1/2","brief_title":"Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers","source_id_and_acronym":"NCT03911973 - BTCRC-BRE18-337","lead_sponsor":"Kari Wisinski","biomarkers":" HER-2 • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 negative • BRCA1 negative","tags":["HER-2 • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • BRCA1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • gedatolisib (PF-05212384)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 04/17/2019","start_date":" 04/17/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-07"},{"id":"5cc7ea58-5792-4936-b0c7-76d10e021a5b","acronym":"PASTOR","url":"https://clinicaltrials.gov/study/NCT02599714","created_at":"2021-01-18T12:37:17.664Z","updated_at":"2024-07-02T16:34:37.661Z","phase":"Phase 1","brief_title":"Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer","source_id_and_acronym":"NCT02599714 - PASTOR","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • vistusertib (AZD2014)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 12/07/2015","start_date":" 12/07/2015","primary_txt":" Primary completion: 03/30/2018","primary_completion_date":" 03/30/2018","study_txt":" Completion: 11/23/2023","study_completion_date":" 11/23/2023","last_update_posted":"2024-06-06"},{"id":"92435528-4415-4d93-8e63-2a53a10bdf30","acronym":"","url":"https://clinicaltrials.gov/study/NCT04250545","created_at":"2021-01-18T20:39:21.304Z","updated_at":"2024-07-02T16:34:58.880Z","phase":"Phase 1","brief_title":"Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04250545","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • ALK • ROS1 • KEAP1 • NFE2L2","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • BRAF V600K • KEAP1 mutation • NFE2L2 mutation","tags":["KRAS • BRAF • ALK • ROS1 • KEAP1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • BRAF V600K • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228) • telaglenastat (CB-839)"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 10/26/2020","start_date":" 10/26/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-04"},{"id":"c4a67b85-d57e-45f1-9a88-e437704888be","acronym":"","url":"https://clinicaltrials.gov/study/NCT04479306","created_at":"2021-01-18T21:30:41.583Z","updated_at":"2024-07-02T16:34:59.204Z","phase":"Phase 1","brief_title":"Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04479306","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L858R + EGFR exon 21 deletion","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L858R + EGFR exon 21 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • sapanisertib (CB-228) • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 06/18/2020","start_date":" 06/18/2020","primary_txt":" Primary completion: 07/27/2023","primary_completion_date":" 07/27/2023","study_txt":" Completion: 07/27/2023","study_completion_date":" 07/27/2023","last_update_posted":"2024-06-04"},{"id":"bd3903e4-47f8-44a5-a2e7-496b069f8567","acronym":"","url":"https://clinicaltrials.gov/study/NCT02208375","created_at":"2021-01-18T10:20:36.481Z","updated_at":"2024-07-02T16:35:02.701Z","phase":"Phase 1/2","brief_title":"mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian","source_id_and_acronym":"NCT02208375","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR • BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation","tags":["ER • PGR • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Truqap (capivasertib) • vistusertib (AZD2014)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 11/11/2014","start_date":" 11/11/2014","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-05-17"},{"id":"c81f4907-3d78-44bf-bbba-6db76728d952","acronym":"","url":"https://clinicaltrials.gov/study/NCT02484430","created_at":"2021-01-29T07:10:20.095Z","updated_at":"2024-07-02T16:35:04.995Z","phase":"Phase 2","brief_title":"Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02484430","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 10/20/2016","start_date":" 10/20/2016","primary_txt":" Primary completion: 12/28/2018","primary_completion_date":" 12/28/2018","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-05-08"},{"id":"bf025afb-cb7b-4218-a07e-2e1a6a998168","acronym":"VICTORIA","url":"https://clinicaltrials.gov/study/NCT02730923","created_at":"2021-01-18T13:22:14.129Z","updated_at":"2024-07-02T16:35:19.665Z","phase":"Phase 1/2","brief_title":"Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)","source_id_and_acronym":"NCT02730923 - VICTORIA","lead_sponsor":"Centre Leon Berard","biomarkers":" ER • PGR • ABCB1","pipe":" | ","alterations":" PGR positive","tags":["ER • PGR • ABCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • vistusertib (AZD2014)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-13"},{"id":"0a5c6ecb-6e8b-4c37-8a56-4472e94bb344","acronym":"","url":"https://clinicaltrials.gov/study/NCT03065062","created_at":"2021-01-18T15:05:53.427Z","updated_at":"2024-07-02T16:35:20.735Z","phase":"Phase 1","brief_title":"Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head \u0026 Neck and Other Solid Tumors","source_id_and_acronym":"NCT03065062","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • gedatolisib (PF-05212384)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 02/28/2017","start_date":" 02/28/2017","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-02-06"},{"id":"a49319c7-fc86-477e-9d18-340184f8a72b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03193853","created_at":"2021-01-18T15:44:59.657Z","updated_at":"2025-02-25T14:50:33.000Z","phase":"Phase 2","brief_title":"TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT03193853","lead_sponsor":"Joyce O'Shaughnessy","biomarkers":" AR","pipe":" | ","alterations":" AR negative","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • albumin-bound paclitaxel • sapanisertib (CB-228) • serabelisib (MLN1117)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 07/18/2017","start_date":" 07/18/2017","primary_txt":" Primary completion: 03/17/2020","primary_completion_date":" 03/17/2020","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2023-08-07"},{"id":"d2a1f497-dc00-456c-bc4d-27ca055c9d89","acronym":"VIKTORIA-1","url":"https://clinicaltrials.gov/study/NCT05501886","created_at":"2022-08-16T12:57:45.738Z","updated_at":"2024-07-02T16:35:41.507Z","phase":"Phase 3","brief_title":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)","source_id_and_acronym":"NCT05501886 - VIKTORIA-1","lead_sponsor":"Celcuity, Inc.","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" ER positive • PIK3CA mutation • PGR positive","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PIK3CA mutation • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Piqray (alpelisib) • fulvestrant • gedatolisib (PF-05212384)"],"overall_status":"Recruiting","enrollment":" Enrollment 701","initiation":"Initiation: 09/30/2022","start_date":" 09/30/2022","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2023-08-01"},{"id":"4e6878e9-d76c-4e3d-9894-9e482c8740b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02049957","created_at":"2021-01-18T09:25:38.733Z","updated_at":"2024-07-02T16:35:56.099Z","phase":"Phase 1b/2","brief_title":"Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer","source_id_and_acronym":"NCT02049957","lead_sponsor":"Calithera Biosciences, Inc","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • fulvestrant • sapanisertib (CB-228) • exemestane"],"overall_status":"Completed","enrollment":" Enrollment 118","initiation":"Initiation: 02/13/2014","start_date":" 02/13/2014","primary_txt":" Primary completion: 06/29/2018","primary_completion_date":" 06/29/2018","study_txt":" Completion: 06/29/2018","study_completion_date":" 06/29/2018","last_update_posted":"2023-02-08"},{"id":"a517e148-0243-41aa-abf4-ba369a1377ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT02756364","created_at":"2021-01-17T17:33:46.971Z","updated_at":"2024-07-02T16:35:56.110Z","phase":"Phase 2","brief_title":"Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy","source_id_and_acronym":"NCT02756364","lead_sponsor":"Calithera Biosciences, Inc","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • sapanisertib (CB-228)"],"overall_status":"Completed","enrollment":" Enrollment 141","initiation":"Initiation: 07/28/2016","start_date":" 07/28/2016","primary_txt":" Primary completion: 11/25/2019","primary_completion_date":" 11/25/2019","study_txt":" Completion: 11/25/2019","study_completion_date":" 11/25/2019","last_update_posted":"2023-02-08"},{"id":"49cd925d-5478-4371-b4b0-a086d238accc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01920061","created_at":"2021-01-18T08:39:47.248Z","updated_at":"2024-07-02T16:36:04.030Z","phase":"Phase 1b","brief_title":"A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)","source_id_and_acronym":"NCT01920061","lead_sponsor":"Pfizer","biomarkers":" HER-2 • KRAS • BRAF","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • BRAF mutation","tags":["HER-2 • KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • Vizimpro (dacomitinib) • gedatolisib (PF-05212384)"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 09/10/2013","start_date":" 09/10/2013","primary_txt":" Primary completion: 01/08/2020","primary_completion_date":" 01/08/2020","study_txt":" Completion: 01/08/2020","study_completion_date":" 01/08/2020","last_update_posted":"2022-09-13"},{"id":"f528e44c-c0ff-4562-9478-599f9db53b2a","acronym":"VIKTORIA-1","url":"https://clinicaltrials.gov/study/NCT05486143","created_at":"2022-08-03T15:55:05.186Z","updated_at":"2025-02-25T20:04:04.784Z","phase":"Phase 3","brief_title":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT05486143 - VIKTORIA-1","lead_sponsor":"Celcuity, Inc.","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" ER positive • PIK3CA mutation • PGR positive","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PIK3CA mutation • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Piqray (alpelisib) • fulvestrant • gedatolisib (PF-05212384)"],"overall_status":"Recruiting","enrollment":" Enrollment 701","initiation":"Initiation: 09/30/2022","start_date":" 09/30/2022","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2022-08-03"},{"id":"c65cf06e-76c6-4405-9194-76740d9fdfff","acronym":"B2151009","url":"https://clinicaltrials.gov/study/NCT02684032","created_at":"2021-01-17T17:24:35.057Z","updated_at":"2024-07-02T16:36:06.521Z","phase":"Phase 1b","brief_title":"A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer","source_id_and_acronym":"NCT02684032 - B2151009","lead_sponsor":"Celcuity, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • letrozole • gedatolisib (PF-05212384)"],"overall_status":"Completed","enrollment":" Enrollment 141","initiation":"Initiation: 06/14/2016","start_date":" 06/14/2016","primary_txt":" Primary completion: 01/19/2022","primary_completion_date":" 01/19/2022","study_txt":" Completion: 01/19/2022","study_completion_date":" 01/19/2022","last_update_posted":"2022-07-27"},{"id":"4af2b883-4b5c-4b1a-b8a8-6f3373185c01","acronym":"","url":"https://clinicaltrials.gov/study/NCT02719691","created_at":"2021-01-18T13:18:17.871Z","updated_at":"2024-07-02T16:36:06.763Z","phase":"Phase 1","brief_title":"Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer","source_id_and_acronym":"NCT02719691","lead_sponsor":"University of Colorado, Denver","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228) • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 05/13/2016","start_date":" 05/13/2016","primary_txt":" Primary completion: 03/18/2020","primary_completion_date":" 03/18/2020","study_txt":" Completion: 03/18/2020","study_completion_date":" 03/18/2020","last_update_posted":"2022-07-25"},{"id":"7b27da0a-d639-42fd-a136-368d479a1f3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02831257","created_at":"2021-01-18T13:53:02.982Z","updated_at":"2025-02-25T15:07:09.140Z","phase":"Phase 2","brief_title":"AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas","source_id_and_acronym":"NCT02831257","lead_sponsor":"Massachusetts General Hospital","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vistusertib (AZD2014)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 08/31/2016","start_date":" 08/31/2016","primary_txt":" Primary completion: 05/31/2019","primary_completion_date":" 05/31/2019","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2022-06-13"},{"id":"8ae6d248-ecbb-408f-8f2f-48c143b00eec","acronym":"","url":"https://clinicaltrials.gov/study/NCT02417701","created_at":"2021-01-17T17:54:54.823Z","updated_at":"2024-07-02T16:36:13.984Z","phase":"Phase 2","brief_title":"Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer","source_id_and_acronym":"NCT02417701","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • KEAP1 • NFE2L2 • CD4","pipe":" | ","alterations":" KRAS mutation • KEAP1 mutation • NFE2L2 mutation","tags":["KRAS • KEAP1 • NFE2L2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 10/06/2016","start_date":" 10/06/2016","primary_txt":" Primary completion: 12/28/2020","primary_completion_date":" 12/28/2020","study_txt":" Completion: 12/28/2020","study_completion_date":" 12/28/2020","last_update_posted":"2022-04-05"},{"id":"e86355f5-bbcf-4d10-89bf-8a9a9cccffcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02626507","created_at":"2021-01-18T12:45:54.371Z","updated_at":"2024-07-02T16:36:17.340Z","phase":"Phase 1","brief_title":"Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer","source_id_and_acronym":"NCT02626507","lead_sponsor":"Hoffman Oncology","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • gedatolisib (PF-05212384) • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 02/15/2022","primary_completion_date":" 02/15/2022","study_txt":" Completion: 03/15/2022","study_completion_date":" 03/15/2022","last_update_posted":"2022-02-09"},{"id":"117e7c26-f674-404d-a2a1-b4771e7bb528","acronym":"ANETT","url":"https://clinicaltrials.gov/study/NCT02988986","created_at":"2021-01-18T14:42:11.237Z","updated_at":"2025-02-25T14:50:23.622Z","phase":"Phase 2","brief_title":"TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer","source_id_and_acronym":"NCT02988986 - ANETT","lead_sponsor":"The Methodist Hospital Research Institute","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • sapanisertib (CB-228)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 04/24/2017","start_date":" 04/24/2017","primary_txt":" Primary completion: 02/01/2019","primary_completion_date":" 02/01/2019","study_txt":" Completion: 03/30/2019","study_completion_date":" 03/30/2019","last_update_posted":"2021-09-22"}]